Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Financing Activities (2019 - 2026)

C4 Therapeutics has reported Cash from Financing Activities over the past 8 years, most recently at $462000.0 for Q1 2026.

  • For Q1 2026, Cash from Financing Activities rose 1104.35% year-over-year to $462000.0; the TTM value through Mar 2026 reached $126.9 million, up 1085.27%, while the annual FY2025 figure was $126.4 million, 178.8% up from the prior year.
  • Cash from Financing Activities for Q1 2026 was $462000.0 at C4 Therapeutics, down from $118.7 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $118.7 million in Q4 2025 and troughed at -$10.8 million in Q3 2023.
  • A 5-year average of $13.7 million and a median of $310000.0 in 2022 define the central range for Cash from Financing Activities.
  • On a YoY basis, Cash from Financing Activities climbed as much as 122606.38% in 2023 and fell as far as 3078.67% in 2023.
  • Year by year, Cash from Financing Activities stood at $47000.0 in 2022, then surged by 122606.38% to $57.7 million in 2023, then plummeted by 99.81% to $112000.0 in 2024, then skyrocketed by 105857.14% to $118.7 million in 2025, then tumbled by 99.61% to $462000.0 in 2026.
  • Business Quant data shows Cash from Financing Activities for CCCC at $462000.0 in Q1 2026, $118.7 million in Q4 2025, and $7.8 million in Q3 2025.